1 roblems of publication bias and questionable
post hoc analyses.
2 otation of variants is typically inferred by
post hoc analyses.
3 tial outcome predictors were identified in a
post hoc analysis.
4 ns and all-cause mortality was assessed in a
post hoc analysis.
5 nt mild bleeding or any severe bleeding in a
post hoc analysis.
6 s intermediate between the two groups in the
post hoc analysis.
7 h specificity (87%) and sensitivity (78%) in
post hoc analysis.
8 reatment with azithromycin in an exploratory
post hoc analysis.
9 MSC viability was tested in a
post-hoc analysis.
10 o- or hyper-methylated locus without further
post-hoc analysis.
11 CI], 0.09 to 0.59; P = 0.002; relative risk [
post hoc analysis],
0.37; 95% CI, 0.16 to 0.84; P = 0.02
12 In a
post hoc analysis,
192/885 (22%) children developed dela
13 In a
post hoc analysis,
a cut-off value of CFT for systemic t
14 In addition, from
post hoc analysis,
a greater proportion of brolucizumab-
15 We did a
post-hoc analysis after complete ICS withdrawal (months
16 In
post hoc analyses among female never smokers, both PM2.5
17 ol to identify missing links, (v) systematic
post-hoc analyses and (vi) an R-Shiny tool to run CellNO
18 ical vs surrogate primary end points, use of
post hoc analyses,
and reporting of age and sex.
19 The present
post hoc analysis assessed the end point of all-cause mo
20 Post hoc analyses associated factors with symptoms and d
21 Post hoc analysis,
between-study differences in patient
22 However, brain fMRI and
post hoc analyses by site suggest that walnuts might del
23 In
post hoc analysis,
clinic visits significantly increased
24 This
post hoc analysis combines the pre-specified subgroups o
25 0.04) were associated with RV dysfunction on
post hoc analysis.
Conclusions: RV dysfunction is associa
26 stimated by a semiparametric model, while in
post hoc analyses,
DAOH and percent DAOH were compared b
27 Post hoc analysis demonstrated significant differences i
28 A
post hoc analysis demonstrated that simvastatin therapy
29 This
post hoc analysis demonstrated the visual outcome benefi
30 Post-hoc analyses demonstrated that it was shifting atte
31 Corrected
post-hoc analyses demonstrated that patients had signifi
32 Results were consistent in a series of
post hoc analyses,
designed to assess potential biases.
33 In
post hoc analysis,
detectable plasma dipyridamole levels
34 Post hoc analyses determined the response rate and durat
35 Post hoc analyses established that PdE concentration inc
36 This
post hoc analysis evaluated the influence of select base
37 Post hoc analysis;
examination of nonrandomized subsets
38 The
post hoc analyses examined the relationship of neural ab
39 This
post hoc analysis examined potential interaction between
40 This hypothesis-generating
post hoc analysis examined the efficacy of eribulin acco
41 This
post hoc analysis examined whether the effects of the SB
42 A
post hoc analysis (
excluding data for 20 patients from t
43 Some
post hoc analyses for exploring any specific pattern of
44 by using a one-way analysis of variance with
post hoc analysis for statistically significant differen
45 A
post hoc analysis for the primary end point considering
46 ection as users want more interpretation and
post-hoc analyses for biomarker detection.
47 A
post hoc analysis found nine (43%) patients in the activ
48 A
post hoc analysis found that, compared to patients with
49 Exploratory
post hoc analyses from a prior trial showed that vericig
50 We included all observational studies and
post hoc analyses from randomized controlled clinical tr
51 We performed
post hoc analyses from the WOSCOPS (West of Scotland Cor
52 In a
post hoc analysis from 10 ODYSSEY trials, greater percen
53 in relation to 90-day clinical outcomes as a
post hoc analysis from a prospective multicentre observa
54 This
post hoc analysis from the EUCLID trial (Examining Use o
55 urgery for left main disease by performing a
post hoc analysis from the multicenter, randomized EXCEL
56 In a
post hoc analysis,
HFpEF patients with LV hypertrophy (n
57 unity-matched controls were included in this
post-hoc analysis if their mid-upper arm circumference h
58 Post hoc analyses in patients who tolerated GDMT were al
59 Here, in a
post hoc analysis in 1147 patients with type 2 diabetes
60 We also performed a
post hoc analysis in which the rates of major complicati
61 Observational data and results from
post-hoc analyses in clinical trials suggest that direct
62 In a
post hoc analysis,
in patients with symptomatic recurren
63 These
post hoc analyses indicate that patients with severe eos
64 Exploratory
post hoc analyses indicated a greater mPEF improvement b
65 Post hoc analyses indicated that greater modulation was
66 Post-hoc analyses indicated that racial differences may
67 However, in a
post hoc analysis,
losartan was associated with improved
68 In a
post-hoc analysis,
mean reductions in LDL cholesterol in
69 In this
post hoc analysis,
mortality steadily increased with inc
70 hs were obtained from the Protocol T 24-week
post hoc analysis (
n = 546).
71 Post hoc analyses of cardiac data from (1) studies in pa
72 Current techniques are limited to
post hoc analyses of fixed tissues.
73 In prespecified and
post hoc analyses of HF and related events, Cox proporti
74 Multiple large observational studies and
post hoc analyses of randomized trials have established
75 Post hoc analysis of (68)Ga-PSMA-11 PET/CT implied a maj
76 AF and long-term risk of CVA by performing a
post hoc analysis of 10-year outcomes of the ART (Arteri
77 This was a
post hoc analysis of 130 prospectively included patients
78 Post hoc analysis of 2 antiviral studies was performed.
79 Post hoc analysis of 2 prospectively followed up pediatr
80 We undertook a
post hoc analysis of 2 randomized clinical trials evalua
81 Post hoc analysis of 2 similarly designed phase 3 trials
82 We performed a
post hoc analysis of 30 participants of a clinical trial
83 We performed a
post hoc analysis of 561 HIV-infected sputum-expectorati
84 A
post hoc analysis of 637 cultures from 610 medical patie
85 This
post hoc analysis of a clinical trial assessed the medic
86 This investigation was a
post hoc analysis of a cohort in the e-ROP Study (a mult
87 In a
post hoc analysis of a multicenter randomized controlled
88 We performed a
post hoc analysis of a phase III placebo-controlled stud
89 In this
post hoc analysis of a prematurely terminated randomized
90 This was a
post hoc analysis of a prospective cohort of critically
91 The present study is a
post hoc analysis of a prospective trial which randomize
92 This was a
post hoc analysis of a prospectively collected cohort of
93 In this
post hoc analysis of a randomized clinical trial which t
94 We performed a
post hoc analysis of a randomized controlled trial of no
95 We performed a
post hoc analysis of a randomized controlled trial of tw
96 HV-6B reactivation after allogeneic HCT in a
post hoc analysis of a randomized controlled trial.
97 Study 3 was a
post hoc analysis of a randomized trial of inhaled aztre
98 ed for treatment of endovascular stroke in a
post hoc analysis of a recent randomized controlled tria
99 A
post hoc analysis of a retrospective cohort including di
100 This investigation was a
post hoc analysis of a subgroup of laser control eyes in
101 , and Participants: This investigation was a
post hoc analysis of a subgroup of laser control eyes in
102 This was a
post hoc analysis of all eyes in the PIONEER undergoing
103 A
post hoc analysis of all pathologic reports from patient
104 This was a
post hoc analysis of an intention-to-treat population of
105 A meta-analysis and a
post hoc analysis of an RCT in patients with stable card
106 In a
post hoc analysis of ARISTOTLE (Apixaban for Reduction i
107 Post hoc analysis of baseline patient characteristics in
108 ne the origin of lactate.Methods: This was a
post hoc analysis of baseline variables of 1,741 patient
109 In a
post hoc analysis of children weighing 65 kg or less, th
110 Post hoc analysis of clinical and laboratory features co
111 A
post hoc analysis of clinical trials of adults with acti
112 l Coherence Tomography, seems to emerge from
post hoc analysis of collected data demonstrating strong
113 In a
post hoc analysis of data collected for prospective obse
114 In a
post hoc analysis of data from a phase III study of the
115 Post hoc analysis of data from HARBOR was undertaken.
116 Post hoc analysis of data from the 36-month prospective,
117 We conducted a
post hoc analysis of data from the TEMPO 3:4 trial.
118 Post hoc analysis of efficacy, safety, and resource util
119 This randomized trial report is based on a
post hoc analysis of extended follow-up beyond that of t
120 This was a
post hoc analysis of eyes in the DISCOVER study undergoi
121 We performed a
post hoc analysis of FIGHT to investigate whether liragl
122 l analyses were conducted using ANOVA with a
post hoc analysis of Fisher's LSD.
123 Post hoc analysis of functionally connected pairs sugges
124 Post hoc analysis of inflammatory and nutritional biomar
125 We performed a prespecified
post hoc analysis of ischemic stroke patients screened f
126 A
post hoc analysis of Medicare Part D data revealed low p
127 In this
post hoc analysis of PARAGON-HF (Prospective Comparison
128 An exploratory
post hoc analysis of participants with a consistent rate
129 We performed a
post hoc analysis of patients enrolled in the DIVA (Drug
130 In a
post hoc analysis of patients with an initially abnormal
131 This
post hoc analysis of phase 3 data further investigated t
132 Post hoc analysis of prospectively collected data.
133 post hoc analysis of risk factors associated with arthri
134 In a
post hoc analysis of samples from an intrapartum azithro
135 In a
post hoc analysis of SPRINT, we defined change in eGFR a
136 from a recent randomized controlled trial, a
post hoc analysis of that trial, a meta-analysis, and a
137 or BITA grafts and outcomes by performing a
post hoc analysis of the ART.
138 A
post hoc analysis of the combined data sets showed that
139 Methods In this
post hoc analysis of the DANISH trial (Danish Study to A
140 Conclusions In this
post hoc analysis of the DANISH trial, ICD therapy was a
141 In this
post hoc analysis of the DEFUSE 2 study, 35 patients wit
142 This was a
post hoc analysis of the Edaravone Phase III Study MCI18
143 We conducted a
post hoc analysis of the Folic Acid for Vascular Outcome
144 We performed a
post hoc analysis of the FOURIER trial (Further Cardiova
145 ients with different ACS phenotypes.Methods:
Post hoc analysis of the ISAACC (Continuous Positive Air
146 This secondary
post hoc analysis of the MAGIC trial included participan
147 nostic factor for overall survival (OS) in a
post hoc analysis of the Mainsail trial.
148 Post hoc analysis of the multicenter TTM-trial.
149 unication in advanced cancer, we conducted a
post hoc analysis of the patient intervention component,
150 This is a
post hoc analysis of the PermiT (Permissive Underfeeding
151 Moreover, a
post hoc analysis of the phase 2 trial of NP001 using th
152 Post hoc analysis of the phase 3 VISTA study in patients
153 Post hoc analysis of the phase III RIDE and RISE studies
154 ncluding 50 patients with dose escalation by
post hoc analysis of the phase III trial of rupatadine f
155 This is a
post hoc analysis of the RE-LY trial.
156 uncontrolled retrospective case series and a
post hoc analysis of the registration trial for temozolo
157 Cross-sectional
post hoc analysis of the Singapore Epidemiology of Eye D
158 In this
post hoc analysis of the Singapore Epidemiology of Eye D
159 Conclusion This
post hoc analysis of the single-center SIESTA trial reve
160 on monitoring for HIV-TB coinfected patients.
Post hoc analysis of the Starting Antiretroviral Therapy
161 weight and follow-up visits and performed a
post hoc analysis of the Treating to New Targets trial,
162 This
post hoc analysis of the trial data aims to investigate
163 We conducted a
post hoc analysis of the vandetanib phase III trial invo
164 A
post hoc analysis of the VISUAL-1 and VISUAL-2 placebo-c
165 We report a
post hoc analysis of this trial after a median follow-up
166 We here report a
post hoc analysis of this trial after a median follow-up
167 However, a Bayesian
post hoc analysis of this trial and a subsequent meta-an
168 Post-hoc analyses of an open cohort from an observationa
169 Post-hoc analyses of clinical trials involving Ixekizuma
170 Epidemiological studies and
post-hoc analyses of clinical trials of corticosteroid t
171 A
post-hoc analysis of 637 cultures from 610 medical patie
172 Post-hoc analysis of a prospective clinical study.
173 Post-hoc analysis of all CYD14/15 trial participants rev
174 We did a
post-hoc analysis of BIOSTAT-CHF, a prospective study in
175 In this report, we did a
post-hoc analysis of cardiovascular and renal outcomes o
176 We conducted a
post-hoc analysis of data from the CANagliflozin cardioV
177 We did a
post-hoc analysis of data, which was completed on Sept 2
178 In this
post-hoc analysis of midnasal pneumococcal carriage in a
179 ied subgroup analysis in August, 2013, and a
post-hoc analysis of non-inferiority and safety in March
180 Post-hoc analysis of patients who underwent pancreatoduo
181 In this
post-hoc analysis of pooled MODIFY I/II data, efficacy e
182 Post-hoc analysis of survival to combined endpoint in SM
183 We did a
post-hoc analysis of the 3 year inhaled Steroid Treatmen
184 Post-hoc analysis of the assessments with Tukey's honest
185 We did a
post-hoc analysis of the coaching-based implementation o
186 In a
post-hoc analysis of the PARADIGM-HF trial, we included
187 However, in a
post-hoc analysis of the primary endpoint, the within-tr
188 In a
post-hoc analysis of the whole study population, of thos
189 This is a retrospective
post-hoc analysis of the YELLOW II trial, comparing pati
190 We conducted
post-hoc analysis of two randomized trials including 685
191 This was a
post-hoc analysis of Women's Health Initiative participa
192 We performed
post hoc analyses on the utility of pretherapeutic and e
193 We conducted a
post hoc analysis on 1,047 patients with PDD from 2 rand
194 low back pain and/or leg pain and performed
post hoc analysis on changes in opioid dosage 12 months
195 We performed
post-hoc analyses on the utility of pre-therapeutic and
196 In this
post hoc analysis,
patients in SAVOR-TIMI 53 (Saxaglipti
197 In this
post hoc analysis,
patients with a GRACE score >140 were
198 Design, Setting, and Participants:
Post hoc analyses performed from May 3, 2016, to June 21
199 In this
post hoc analysis,
poor platelet recovery was associated
200 Post hoc analyses provided weak evidence of increased mo
201 This
post hoc analysis provided additional evidence for the r
202 In a
post-hoc analysis,
rates of patients with inappropriate
203 In a
post-hoc analysis,
reduction of mortality was more evide
204 In
post hoc analyses restricted to patients enrolling under
205 Post hoc analyses revealed a significant difference betw
206 Post hoc analyses revealed maximum efficacy at 2 weeks (
207 Post hoc analyses revealed significant differences in th
208 The
post hoc analyses revealed that in the dorsal mid-insula
209 Post hoc analyses revealed that OB individuals exhibited
210 Post hoc analyses revealed that the Parkinson disease gr
211 A
post hoc analysis revealed a more complex picture where
212 However,
post hoc analysis revealed a significant survival benefi
213 Post hoc analysis revealed clear CD in most of these eye
214 Post hoc analysis revealed this association is sex speci
215 Post-hoc analyses revealed a reduced annual relapse rate
216 ANOVA and
post-hoc analyses revealed that OBP had significantly lo
217 Post-hoc analyses revealed that the glutamine/glutamate
218 Post-hoc analyses revealed this effect to occur in corti
219 th contemporaneous psychotomimetic symptoms;
post-hoc analysis revealed that ketamine was the predomi
220 This
post hoc analysis reveals that treatment with denosumab
221 In
post hoc analysis,
right ventricular stroke volume incre
222 Post hoc analyses showed that the relationship between I
223 However, a
post hoc analysis showed evidence of effect modification
224 Post hoc analysis showed that KOM had higher SBP than KO
225 Post hoc analysis showed that the effect was greater in
226 A
post hoc analysis showed that this association reflected
227 al, which included heterogeneous patients, a
post-hoc analysis showed significantly worse overall sur
228 Post-hoc analysis showed that the T1/2 of gastric emptyi
229 In
post hoc analyses,
significant differences in favor of a
230 Post hoc analysis,
small sample size, and examination of
231 In
post hoc analysis,
State-Trait Anxiety Inventory State g
232 In a
post hoc analysis,
stent length was the only subgroup of
233 Post hoc analyses stratified patients with FND by mental
234 RATIONALE:
Post hoc analyses suggest that blood eosinophils have po
235 d not meet its primary endpoint, exploratory
post hoc analyses suggest that selonsertib may slow diab
236 Although the VHS had no overall effect,
post-hoc analyses suggest VHS might be effective in redu
237 These results, confirmed by a
post hoc analysis,
suggest that uncertainty is introduce
238 Post hoc analyses suggested that LNS benefited gross mot
239 Post hoc analyses suggested that this effect was specifi
240 Post hoc analysis suggested an increased risk for recurr
241 noninferiority analysis was indeterminate, a
post hoc analysis suggested that VA improvement with thi
242 Post hoc analysis suggests a possible association betwee
243 This
post hoc analysis suggests that adalimumab is associated
244 Importantly, this
post hoc analysis supports the notion that patients with
245 In ITT-IS (
post-hoc analysis),
the latter was statistically signifi
246 In planned
post hoc analyses,
the authors examined associations bet
247 In
post hoc analyses,
the effect of treatment seemed to be
248 In a
post hoc analysis,
the 2-year cumulative incidence of he
249 tish COmputed Tomography of the HEART Trial)
post hoc analysis,
the presence of adverse plaque (posit
250 In a
post hoc analysis,
the proportion of IFN-switch patients
251 In a
post hoc analysis,
the relationship between average on-t
252 By a
post hoc analysis,
there were no statistically significa
253 We performed
post hoc analyses to determine whether high PRS for CAD
254 We performed
post hoc analyses to evaluate the effect of humanized mo
255 We conducted a
post hoc analysis to assess the effect of coadministrati
256 precise locations in time and space and use
post hoc analysis to determine behavioral responses to s
257 We performed a
post hoc analysis to determine whether there was a sex d
258 A
post hoc analysis to discern sources of inter-individual
259 We did a
post-hoc analysis to analyse patterns of recurrence with
260 This
post hoc analysis used data from 291 patients treated wi
261 CI, 10% to 37%) by Kaplan-Meier estimate in
post hoc analysis using definitions and methods consiste
262 CI, 7% to 26%) by Kaplan-Meier estimate in a
post hoc analysis using methods consistent with historic
263 In
post hoc analysis using period-wise baselines, supine SV
264 In
post hoc analysis using unique pathogens typed by pulsed
265 In
post hoc analysis,
video laryngoscopy was associated wit
266 In
post hoc analyses,
VM CPM and time spent in moderate/vig
267 ) in G eyes with normal PSD(C24-2) values, a
post hoc analysis was combined with a CD reference stand
268 This exploratory
post hoc analysis was conducted between October 1, 2011,
269 Post hoc analysis was conducted of prospectively collect
270 A
post hoc analysis was conducted with the patients with A
271 A
post hoc analysis was performed of a double-blind, rando
272 A
post hoc analysis was performed of the Efficacy of Vasop
273 A
post hoc analysis was performed of the phase 2 trial of
274 A
post hoc analysis was performed on 721 subjects (age, 68
275 A
post hoc analysis was performed on a prospective, multic
276 A
post hoc analysis was performed to assess whether these
277 The aim of this
post hoc analysis was to assess the occurrence of all (f
278 The aim of this
post hoc analysis was to evaluate sex-specific differenc
279 Using
post-hoc analyses we identified two groups of subjects w
280 In
post hoc analyses,
we aimed to identify associations bet
281 In a
post hoc analysis,
we also compared results to the EFS r
282 In a
post hoc analysis,
we also compared TSPO availability be
283 In this
post hoc analysis,
we assessed the association of baseli
284 In a
post hoc analysis,
we compared the risk of 3 composite b
285 In this
post hoc analysis,
we investigated the relationship betw
286 In a
post hoc analysis,
we performed a cross-sectional observ
287 In a
post-hoc analysis,
we also investigated the effects on g
288 In this
post-hoc analysis,
we analysed complete clinical respons
289 In a
post-hoc analysis,
we analysed survival at 7 days after
290 In a
post-hoc analysis,
we found difference in blood pressure
291 In this
post-hoc analysis,
we test the hypothesis that the overa
292 ng Cox proportional hazard models, and, in a
post-hoc analysis,
we used logistic regression models to
293 In
post hoc analyses,
weight loss of 5 kg or more within th
294 In this
post hoc analysis,
weight change at 12 and 24 months was
295 Post hoc analyses were carried out to evaluate safety an
296 Subsequent
post hoc analyses were conducted to address further cuto
297 Results:
Post hoc analyses were performed for 660 participants (m
298 Post hoc analyses were performed to explore the possible
299 ears of follow-up data were included in this
post hoc analysis,
which was based on a cohort of 100 di
300 Post hoc analysis within a randomized trial, the Startin